ABSTRACT
Osteoporosis is a complex multi-factorial bone disorder with a strong genetic basis. It is the most common, severe, progressive skeletal illness that has been increasing particularly in developed countries. Osteoporosis will no doubt constitute a serious clinical burden in healthcare management in the coming decades. The genetics of osteoporosis should be analyzed from both the disease susceptibility and the pharmacogenetic treatment perspectives. The former has been widely studied and discussed, while the latter still requires much more information and research. This paper provides a synthesis of the literature on the genetics of osteoporosis and an update on progress made in pharmacogenetics of osteoporosis in recent years, specifically regarding the new molecular targets for antiresorptive drugs. In-depth translation of osteoporosis pharmacogenetics approaches to clinical practice demands a new vision grounded on the concept of "theranostics". That is, the integration of diagnostics for both disease susceptibility testing as well as for prediction of health intervention outcomes. In essence, theranostics signals a broadening in the scope of inquiry in diagnostics medicine. The upcoming wave of theranostics medicine also suggests more distributed forms of science and knowledge production, both by experts and end-users of scientific products. Both the diagnosis and personalized treatment of osteoporosis could conceivably benefit from the emerging postgenomics field of theranostics. 
INTRODUCTION
Osteoporosis is a systemic skeletal disease characterized by low bone mass and deterioration in the microstructure of bone tissue, which causes bone fragility and the consequent increase in fracture risk (NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, 2001 ). The disability resulting from osteoporosis in Europe is greater than the combined disability of all non-lung cancers (Lenise A., 2010) . The lifetime fracture risk of a patient with osteoporosis is as high as 40%, and fractures most commonly occur in the hip, spine or wrist (Rachner TD., 2011) . Hip fracture (HF) is the most threatening because of its high mortality rate which can reach 30% the year after the fracture (Franzo A., 2005) .
Osteoporosis is a multifactorial and polygenic disease (Ralston SH., 2002) , so the individual likelihood of having a fracture depends on the combination of several risk factors, such as low bone mineral density (BMD) and genetic predisposition (Cummings SR., 1995; Rojo K., 2010) .
The consequences of osteoporotic fractures generate significant direct and indirect economic impact on the level of healthcare needed. It is important to note that the impact of osteoporotic fractures on the economy has not been extensively studied and evaluated in hospitals. Estimations of the costs associated with hip fractures vary depending on the parameters analyzed. Hospital costs have demonstrated expenses that range from 9.000 (Pike C., 2010) to approximately 40,000 Euros (year/patient) (The Economic Cost of Hip Fracture in the UK, 2000) . The studies do not take into account expenses such as hospitalization, ambulance, and primary care. Currently, these costeffectiveness analyses are starting to become increasingly important for global hospital management (Leslie WD., 2011; Blume SW., 2011) . One of the best and most widely-used clinical determinants of the bone status of an individual is the BMD measurement (Kanis JA., 2002) , which is considered a valid parameter for diagnosing osteoporosis and predicting fracture risk (Cummings SR., 2002) . Although many external factors play fundamental roles in determining BMD, it has been estimated that over 50% of women and 70% of men who have suffered fractures did not previously have osteoporotic BMD values determined (Nguyen ND., 2007) . Furthermore, in studies of osteoporosis therapy, increases in BMD were not linearly proportional to fracture risk reductions. The change in BMD induced by antiresorptive drugs explains approximately 15% of the reduction in fracture risk (Delmas PD., 2004) . The International Osteoporosis Foundation projects that measure BMD using Dual-Energy X-ray Absorptiometry (DEXA) are believed to overestimate BMD by 20% to 50% (Johnell O., 2006) and are poor predictors of fracture in individuals. Advances in imaging techniques of factors such as cortical porosity with high-resolution peripheral CT may allow volumetric bone-density data to better predict bone strength, and thus fracture risk (Zebaze RM., 2010).
Decision-making methods such as the fracture-risk assessment tool (FRAX) have integrated clinical risk factors with DEXA-based BMD to predict an individual's 10-year risk of sustaining a hip fracture, as well as the 10-year probability of having a major osteoporotic fracture, clinically-defined as spine, forearm, hip, or shoulder fracture. Each country adjusts this algorithmic tool to the data based on geographic variation Version 3.0 of the FRAX has shown to give lower probability estimates for major osteoporotic fracture and hip fracture than version 2.0, but has had little impact on rank order of risk. This tool bridges the gap between the parameters for diagnosing osteoporosis and identifying individuals with structurally compromised bone that causes an increased risk of fracture. However, as it is a recently-developed scale, it has F o r P e e r R e v i e w 6 limitations because it does not contain some important risk factors associated with falls and fractures. These risk factors may include high consumption of specific drugs like inhibitors of the proton pump, and benzodiazepines.
It is necessary to consider that discovering genes that affect osteoporosis comprise two main areas: genetics of disease susceptibility and pharmacogenetics of drug response. This review will approach pharmacogenetics of drug response and its implications to current clinical practice including a review of the validation process, which allows the development of specific guidelines. Future perspectives of pharmacogenetic research should be supported by validation processes, which would involve the control of different parameters related to accuracy, precision, and repeatability of the genotyping methods. We will first give a brief overview of the genetics of osteoporosis, and then proceed to studies in pharmacogenetics of osteoporosis.
GENETICS OF OSTEOPOROSIS
The genetics of osteoporosis has revealed promising associations between many polymorphisms in candidate genes and bone traits, both quantitative and qualitative.
The association of many candidate genes with BMD and osteoporotic fracture risk has become controversial, owing to the failure of independent replication, possibly due to insufficient statistical power and false-positive results. Genes involved in common bone formation/destruction pathways have been described as being related to the risk of osteoporosis, the risk of hip and vertebral fractures, and to BMD values. Therefore, these gene variants could affect homeostasis and bone structure, and as a result, BMD values. Given the available studies from different reviews and the clinical importance of osteoporosis, this section will focus on those pathways and genes most frequently studied in relation to BMD and osteoporosis fracture risk.
In this context, one of the active pathways is the osteoclastogenesis pathway, which is related to the process of bone remodeling through the activity of OPG, RANK and RANK-L loci (Hofbauer LC., 2000) . RANK and RANK-L play a significant role in the signaling enhancement pathway of the number, survival and activity of osteoclast.
OPG acts as a competitor of RANK in binding to the RANK-L receptor, thus inhibiting the activity of osteoclasts (Jones HD., 2002; Pearce SH., 1997).
The Wnt signaling pathway participates in the process of bone formation and resorption by including transmembrane proteins such as LRP5, LRP6 (Tamai K., 2000) and ITGB3. The Wnt signaling pathway is essential for the maturation of osteoclasts, and thus for bone resorption (Teitelbaum SL., 2000) .
Likewise, the active metabolite of vitamin D (1α,25(OH)2D3) plays a fundamental role in bone metabolism by binding to its VDR receptor. VDR regulates calcium homeostasis through the binding and nuclear translocation of the 1α,25[OH]2D3, in order to regulate bone turnover and increase gut calcium absorption (Wesley P., 2002) .
Synthesis of estrogens is essential for the acquisition and maintenance of bone mass, predominantly in women (Ichikawa S., 2005) . The physiological functions of estrogens are performed when they bind to the α-and β-receptors (ESR-α, ESR-β), the final biological impact being expressed in both osteoblasts and osteoclasts (Bord S.,
2001).
Moreover, collagen is an important component of the body's structural proteins.
COL1A1 is the largest and most abundant constituent of all bone tissue proteins, and In homeostasis, the calcium-phosphorus pathway is the Calcium Sensing Receptor (CaSR), which belongs to the G-protein coupled receptor super family, and serves as a sensor of the extracellular calcium levels in different tissues (Pearce SH., 1997) . It is expressed in bone cells, and recent data indicate that this receptor can be involved in the regulation of osteoclastic bone resorption (Kameda T., 1998).
The key enzymes in the mevalonate pathway are FDPS and GGPS1. These enzymes are targets in the isoprenoid biosynthesis. This pathway has been demonstrated to be involved in the regulation of mechanisms by which bisphosphonates induce apoptosis of osteoclasts (Marini F., 2008; Choi HJ., 2010) .
The genetic analysis in osteoporosis includes the use of high throughput whole genome expression microarray applications (a technology that allows researchers to study the expression of many genes at once). This technology has found specific upregulated or down-regulated genes, and has discovered putative clinical biomarkers. A compilation of the main genetic factors described through potential candidate gene, genome-wide association studies (GWAS) and meta-analyses related (Hsu Y., 2010; 31:629-62; 1192:181-9; Mencej-Bedrac S., 2009; Reppe S., 2010; Uitterlinden AG., 2006; Ji GR., 2010; Fang Y., 2006; Macdonald H., 2006; Mann V., 2003; Yazdanpanah N., 2007; Kapur K., 2010; Tsukamoto K., 2000 ; Harding B., 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The conflicting results compiled for each pathway are possibly owing to the complexity of the osteoporosis phenotype itself, added to the limitations in the molecular tools available. These conflicts should be approached by using improved screening, risk assessment, diagnosis and treatment initiation (MacLaughlin E., 2010) .
In this regard, an important contribution would be the complementary use of validated pharmacogenetic tests in clinical practice (Lamberts S., 2009; Van Straaten T., 2010) .
PHARMACOGENETICS OF OSTEOPOROSIS Osteoporosis Pharmacotherapy:
The therapeutic breakthroughs that have emerged for the treatment of osteoporosis may improve bone quality (the constellation of bone architecture, bone turnover, and damage accumulation and mineralization) and bone quantity (integration of bone mass, estimated by BMD). These breakthroughs are within a range of pharmacological alternatives, which are used for prevention of osteoporotic fractures (Delmas PD., 2005 (Rachner TD., 2011; Lewiecki EM., 2011) . Of these molecular drugs, only Denosumab has been approved by the FDA and EMEA for osteoporosis treatment.
Pharmacogenetics of Osteoporosis Treatment
The great majority of association studies have investigated only those genes which affect BMD, bone turnover marker variation, and fracture risk; they could be independent from genes affecting drug responses (adverse affect and efficacy limitations).
The field of pharmacogenetics, which represents the use of individual genetic data to predict the outcome of a drug treatment in relation to efficacy and adverse effects, could be a valuable avenue of study (Gervasini G., 2010) The variability in osteoporosis drug response is much more complicated than simple variability in BMD, bone turnover markers or fracture risk becauseit is necessary to consider other intrinsic characteristics of the patient (morbidity, enviromental factors) that impact the kinetics and dynamics of the drug, and therefore the end-of-treatment response. Thus, it will be very important in future work to define the phenotypes of Due to the controversial results of the studies of expression and to potential concern to clinicians and patients in non-responders to osteoporosis therapy (Lewiecki EM., 2003) the emerging field of pharmacogenetics is very useful for refining and optimizing osteoporosis drug treatment. Pharmacogenetics could potentially allow the identification of the most effective drug and dose for each patient in terms of beneficial and adverse effects, based on the single genotype expression. In order to develop this area, the study of pharmacogenetics of osteoporosis should include the understanding of molecular mechanisms of drug action, the identification of drug response candidate genes and their variants, and the expansion towards clinical trials that include patients' genetic profiles. These approaches could provide useful tools to tailor decisions about osteoporosis drug treatments in order to maximize the health and well-being of osteoporotic patients. As noted in the studies above, research in pharmacogenetics of osteoporosis has been conducted mainly with antiresorptive drugs. This may be because important clinical guidelines have recommended the use of these drugs for primary and secondary prevention of osteoporosis and osteoporotic fractures. As described in the analyzed studies, the effect of antiresorptive drugs will depend primarily on the genotype expressed in the patient. It is possible that the difference in the response of each drug in relation to genetic polymorphisms is related to the mechanism of action.
Recent studies on Pharmacogenetics of antiresorptives:
In order to update the studies in pharmacogenetics of antirresorptive drugs, this section will analyze in detail the studies performed in the last four years regarding the response of these drugs depending on the genotypic characteristics of the patients. Table   2 summarizes the studies based on pharmacogenetics of antiresorptives.
Six novel studies specifically related to pharmacogenetic osteoporosis treatment response merit special consideration. One of these studies, (2008), evaluated the effects of the rs1800012 (G>T) SNP of the COL1A1 gene on BMD response to at least 3 years of low-dose hormone replacement therapy in 111 postmenopausal Turkish women (Simsek M., 2008) and demonstrated that the increase in lumbar BMD and femoral BMD were higher in women with the homozygous GG genotype compared to those with the heterozygous genotype.
In the same year, a study of 234 osteoporotic Danish women associated the rs2297480 (A>C) SNP of FDPS, the molecular target of amino-bisphosphonates in osteoclasts, with the response to 2-year amino bisphosphonate treatment . They found that subjects with the homozygous CC genotype showed a decreased response by urinary Crosslaps after two years, but not after one year of aminobisphosphonate therapy (Alendronate or Ibandronate) when compared to the heterozygous AC and to the homozygous AA genotypes. However, FDPS polymorphism did not show any relationship to baseline spinal and femoral BMD.
In 2009, a study analyzed the influence of the rs3736228 (C>T) and rs4988321 (G>A) polymorphisms of the LRP5 gene in a cohort of 249 osteoporotic or osteopenic men (Kruk M., 2009) . The results showed that the rs3736228 (C>T) polymorphism was associated with hip BMD in osteoporotic men before treatment. However, there was no association between these polymorphisms and BMD and bone turnover response after 2 years with risedronate treatment.
In the same year, 80 postmenopausal women were studied to determine if the A163G (genotype: AA, AG, GG) and T245G (genotype: TT, GT, GG) polymorphisms (Wang C., 2009 ). This study observed that after 12 months of treatment, the percentage of BMD change at the femoral neck was higher in genotype AA, while at site T245G, the percentage of BMD change at inter-troche and total hip were higher in genotype TT, concluding that both genotypes show a better therapeutic effect to alendronate.
In 2010, a study of 144 osteoporotic Korean women (Mencej-Bedrac S., 2009), investigated whether genetic polymorphisms of FDPS (rs2297480 and rs11264361) or GGPS (the rs3840452 and rs3841735) genes were associated with the response to alendronate or risedronate in terms of changes in lumbar spine and femoral neck BMD.
After 1 year of treatment, it was found that women with two deleted alleles of GGPS1 -8188A ins/del (rs3840452) had significantly higher femoral neck BMD at the baseline compared with those with one or no deleted alleles. The response rate of women with two deleted alleles of GGPS1 -8188A ins/del was significantly lower than the rate of women with one or no deleted alleles. Moreover, women with two deleted alleles of GGPS1 -8188A ins/del had a 7-fold increased risk of non-response to bisphosphonate therapy compared to women with other genotypes in GGPS1 -8188, after adjusting for 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Global results from these studies suggest that patient genotyping could be useful to target subjects most likely to respond to osteoporosis drug treatments in terms of BMD and bone turnover marker changes. However, association studies can have some limitations, such as inadequate sample size or sampling errors, genetic differences between ethnic groups, the presence of gene-gene and/or gene-environment interactions acting as confounding factors, the complexity of genome and gene regulation (epigenetic factors, somatic mutations, microRNAs), frequent accidental statistical association (not due to a real association between genotype and phenotype), and the lack of independently replicated studies. For all these reasons, no definite gene variations have conclusively been shown to be responsible for the regulation of any antiosteoporosis drug responses. This research has contributed to the understanding of this disease and has demonstrated the influence of genetic polymorphisms in response to antiresorptive treatment. For a proper and efficient application to clinical practice, it is essential to consider the key issues that will be discussed below.
Adverse drug reactions associated with genetic factors
Drugs do not always reach their therapeutic target because they are not equally effective in all patients, and may lead to a variety of adverse effects.
Although osteoporosis drugs are effective in the majority of cases, most are associated with adverse effects (Rizzoli R., 2011) that render long-term administration and adherence problematic (Siris ES., 2009). Several genes have been evaluated that could be related to these adverse effects. Table 3 shows the main side effects of treatments for osteoporosis (antiresorptive and anabolic drugs). side effect of bisphosphonates is the development of osteonecrosis of the jaw (ONJ), which is the only side effect associated with genetic factors (Kennel KA., 2009 ). The incidence of ONJ in patients treated for osteoporosis is low (0.1%) while the incidence in cancer patients treated with high doses of intravenous drugs is higher (3-10%) (Reid IR., 2009; Franken AA., 2001) . During the last 4 years, 6 genes have been proposed to be involved in the risk of developing ONJ (Sarasquete ME., 2008; Sarasquete ME., 2009; Lehrer S., 2009; Katz J., 2011; Marini F., 2011) and the most relevant of these studies are summarized in Table 4 .
One GWAS determined the role of genes in the pathogenesis of ONJ after 2 years of intravenous BP treatment (pamidronate or zaledronate), carried out in 2 groups of patients with multiple myeloma (22 with ONJ and 65 without) (Pietschmann P., 2009 ). Homozygosis for the T allele of the CYP2C8 rs1934951 (C>T) was associated with an increased risk of developing ONJ. Among genetic factors, CYP2C8 polymorphisms are arising as a promising risk factor, and the bisphosphonate-related ONJ can be predicted by an association of genetic and environmental risk factors (Pietschmann P., 2009; Patsch JM., 2011) . However, this conclusion has not been confirmed by studies on an independent series of patients, so it remains to be seen if that association is a consequence of the genetic background and/or environmental factors unique to the population studied. Despite the interesting contribution of this preliminary study through a GWAS, variability in the genes encoding CYP2C8 would not play a role in the metabolism of B, because these drugs do not undergo any physical-chemical modification (Gong L., 2011).
Another study (Haney E., 2008) proposed the matrix metalloproteinase 2 (MMP2) protein as the candidate gene for bisphosphonate-induced ONJ. The study determined whether any abnormalities in serum bone markers are related to 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Genetic variations in a population create an impressive spectrum of phenotypic diversity, particularly when changes in diet or environment are superimposed on the population. GWAS have become powerful tools for linking sequence variants with overlying systems level phenotypes, but they do not provide insight into the mechanisms through which genetic variation drives phenotypic variation (Voy BH., 2011). Systems genetics is an emerging discipline that provides a means to fill this knowledge gap by assembling a hierarchy of interactions among genes, proteins, and other intermediate phenotypes that manifest themselves as phenotypic variations.
On the other hand, no conclusive results have determined whether there is a difference in the response to the treatments used for osteoporosis, taking into account age, gender, and environmental factors (disease, calcium intake, exercises, among others) or if none of these factors are associated with or influenced by genetics.
However, it is necessary to consider some aspects that will be described below. Osteoporosis is an age-related disease with several gender-specific differences, more prevalent in women than men; however, once a hip fracture has occurred, mortality is higher in men (Rojo K., 2010). Differences in sex hormone production, especially the abrupt decline of estrogens in women, are responsible for inter-gender differences in the pathophysiology of osteoporosis.
The treatment of osteoporosis also differs by gender; therapy options have been studied only in women (Pietschmann P., 2009) . Men have no pharmacological protection from the disease (Patsch JM., 2011) . Therefore, the treatment in men is understudied and the magnitude of the impact of male osteoporosis has been also underestimated (Haney E., 2008) . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Government and External Regulation 6) Genetic findings must be supervised and approved by the appropriate public entity.
They should allow the implementation of specific and reliable tests for those valid biomarkers that have demonstrated association with the safety and efficacy of therapy.
7) The provision of specific recommendations and guidelines from an expert consortium 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Other important considerations must be taken into account before the translation of pharmacogenetic achievements can be used in routine clinical practice, such as molecular biology pharmacogenetic formation, ethical-legal issues, quality management in genetic test laboratories, ISO norms, and cost-effective successful strategies.
Clinicians must be properly informed for the administration of and application of the requirements for genetic tests. Moreover they must have the proper infrastructure required for analysing the sample and interpretation of results, and coordinating themselves. Thus, training at the undergraduate and graduate level must be enhanced. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Future perspectives
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